Finkler N J, Muto M G, Kassis A I, Weadock K, Tumeh S S, Zurawski V R, Knapp R C
Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, Massachusetts.
Gynecol Oncol. 1989 Sep;34(3):339-44. doi: 10.1016/0090-8258(89)90169-8.
Twenty patients with recurrent or persistent epithelial ovarian cancer failing conventional therapies were treated with a single intraperitoneal injection of iodine-131-labeled OC 125 monoclonal antibody. Rare acute side effects were nausea and mild diarrhea. At doses up to 120 mCi of iodine-131, median white blood cell and platelet count nadirs were 3.6k/microliters and 187k/microliters, respectively. Two patients acquired thyroid toxicities despite thyroid blockage with "cold" iodine. One patient had transient TSH elevation while remaining clinically euthyroid, and 1 patient developed activation of a thyroid nodule and clinical hyperthyroidism. Dose-limiting toxicity has not yet been observed. Twelve of 20 patients are alive 3 to 17 months following therapy. Tumor progression was noted in the majority of patients, although 3 patients had documented decreases in tumor burden of short duration. We conclude that, at the doses examined, iodine-131 OC 125 can be safely administered intraperitoneally.
20例复发性或持续性上皮性卵巢癌患者在传统治疗失败后，接受了一次腹腔注射碘-131标记的OC 125单克隆抗体治疗。罕见的急性副作用为恶心和轻度腹泻。在碘-131剂量高达120毫居里时，白细胞计数和血小板计数的中位数最低点分别为3600/微升和18.7万/微升。尽管用“冷”碘进行了甲状腺阻滞，仍有2例患者出现甲状腺毒性。1例患者促甲状腺激素短暂升高，但临床仍处于甲状腺功能正常状态，1例患者甲状腺结节激活并出现临床甲亢。尚未观察到剂量限制性毒性。20例患者中有12例在治疗后3至17个月存活。大多数患者出现肿瘤进展，尽管有3例患者记录到肿瘤负荷在短时间内有所下降。我们得出结论，在所研究的剂量下，碘-131 OC 125可安全地腹腔内给药。
